The rapid growth of GLP-1 receptor agonists, dual agonists and other emerging therapies is accelerating drug development across obesity and type 2 diabetes. At the same time, sponsors face increasing pressure to demonstrate more than just weight loss or glycemic control. This webinar will explore how phase-appropriate endpoint strategies can support stronger development decisions and more differentiated evidence across obesity clinical trials.
Development teams increasingly need to understand how a therapy affects the whole patient, including symptoms, treatment experience, glucose patterns, body composition, organ health and cardiovascular safety. However, the questions sponsors need to confidently answer in early-phase trials differ from those addressed in larger Phase II and Phase III programs.
Join the featured experts in eCOA, cardiac safety and medical imaging to learn how phase-appropriate endpoint solutions that generate high-quality, informative data can support critical decisions. From detecting early safety and efficacy signals informing dose selection, go/no-go and study design decisions, to characterizing treatment benefit and risk building a differentiated, regulator-ready evidence package, implementing the right endpoint strategy and technologies is paramount.
Register to learn how an integrated, phase-appropriate endpoint strategy can help teams identify meaningful signals earlier, reduce development uncertainty and generate stronger evidence for regulatory review and product differentiation
Speakers
Todd Rudo, MD, EVP, Chief Medical Officer, Clario
Dr. Todd Rudo is EVP and Chief Medical Officer at Clario, providing medical and scientific leadership across the organization. He has nearly 20 years of clinical cardiology and pharmaceutical research experience, with a career predominantly focused on drug safety.
Dr. Rudo has board certifications in cardiology, cardiac electrophysiology, nuclear cardiology, adult echocardiography and internal medicine. His team provides expert consulting to clients on scientific and regulatory strategy, and ensures Clario’s product portfolio is scientifically robust, generating high-quality clinical trial endpoint data. Dr. Rudo has a particular interest in applying innovative technologies to improve the scientific rigor of clinical trials, while maintaining focus on the customer experience, including minimizing patient and site burden.
Message Presenter
Vic Patel, MD, PhD, VP, Chief Medical Officer, Cardiology, Clario
Dr. Vic Patel is board-certified in Cardiology with a PhD in Biophysics and has done extensive research on arrhythmia mechanisms. For 11 years, he served as a Faculty Member at U. Penn. School of Medicine, where he directed the Molecular Arrhythmia Research program and practiced clinical electrophysiology.
Dr. Patel spent the next eight years in drug development and cardiac safety as a Clinical Development Leader and therapy area head across all phases. At Clario, Dr. Patel oversees Cardiology Consulting, ECG/Holter core lab services and leads the Biostatistics and Medical writing groups.
Message Presenter
Brian K. Rundle, PhD, Scientific Advisor, Clario
Brian Rundle is a Neuropsychologist and Scientific Advisor within Clario’s eCOA Science & Consulting team, where he helps pharmaceutical and biotechnology sponsors optimize the collection of patient-centered and cognitive outcomes data in clinical trials. His work focuses on the design and implementation of research technology that balances regulatory compliance, scientific rigor and intuitive user experiences to maximize data quality and participant engagement.
With expertise spanning neuroscience, cognitive assessment, metabolic disorders and connected devices, Brian works closely with sponsors to develop fit-for-purpose solutions for complex clinical research programs. Leveraging a unique blend of scientific, technical and project management experience, he provides strategic guidance on study design, endpoint selection and clinical trial technologies that support successful drug development.
Message Presenter
Mark W. Tengowski, DVM, MS, PhD, Director, Medical & Scientific Affairs, Medical Imaging, Clario
Dr. Mark W. Tengowski’s current responsibilities include Clinical Development and Trial Experiences in SLD/MASH (formerly NAFLD/NASH) and biliary cholangitis; Crohn’s disease, perianal fistula, ulcerative colitis; osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, spondyloarthritis, psoriatic arthritis and bone age; and women’s health including endometriosis, uterine fibroids, endometrial thickness and breast volume and density using various MRI, XR and CT imaging and clinical response assessments.
Dr. Tengowski began his industry career with Pfizer (1999-2007) working in Drug Safety Evaluation (Groton) and Global Clinical Technologies (Ann Arbor). In 2007, he began his imaging core lab service starting at VirtualScopics (2007-2013) and Clario (formerly Bioclinica/ERT, 2016 to present).
Dr. Tengowski is a 1992 graduate of the University of Wisconsin School of Veterinary Medicine with graduate training in Pharmacology (MS, 1994) and Endocrinology & Reproductive Physiology (PhD, 1997), both from the UW-Madison Graduate School. Dr. Tengowski holds veterinary medical licenses in WI and NY and is USDA-accredited (Category II). He is a member of the AASLD.
Message PresenterWho Should Attend?
This webinar will benefit professionals in the following fields with the following job titles:
- CEOs/Chief Medical Officers/Chief Scientific Officers
- Clinical Data Managers/Clinical IT/Clinical Monitoring
- Clinical Operations/Clinical Development (early phase)
- Clinical Research/Clinical Pharmacologists/Clinical Scientists
- Data Science
- Digital Health/Innovations/Operations
- Health Economics and Outcomes Research
- Imaging Scientists/Medical Affairs/Medical Monitor/Head of Development for Program
- Neuroscience Clinical Trials Professionals
- PK Experts/Protocol Managers/Regulatory Affairs
- Professionals in the field of Multiple Sclerosis
- Sr. Managers, Trial Initiation
What You Will Learn
By attending this webinar, attendees will learn how to:
- Build a phase-appropriate endpoint strategy that integrates patient-reported outcomes, glucose monitoring technologies (BGM & CGM), cardiac and imaging data to support the critical decisions required across the development cycle
- Connect the subjective patient experience with objective glucose data by studying symptoms, medication timing, fasting status, rescue actions and connected glucose readings. Attendees will also learn how this data can reveal early safety, tolerability and efficacy signals, inform dose selection and study design and strengthen the late-phase treatment-benefit narrative
- Evolve cardiac safety assessments across development, from focused QTc and heart-rate evaluation in early safety trials to consistent, scalable collection of 12-lead ECG and blood-pressure data in later development
- Select the right imaging strategy for Phase II and Phase III trials evaluating obesity, body composition analysis, impact on fatty liver disease and the broader physiological effects of weight-loss therapies
- Generate differentiating evidence beyond the standard body weight and glycemic control measures leveraging innovation modalities such as MRI-PDFF, MR elastography, organ volumetry, visceral and subcutaneous adipose tissue analysis and functional MRI
Xtalks Partner
Clario
Clario, part of Thermo Fisher Scientific, is a leading provider of endpoint data solutions to the clinical trials industry, generating high-quality clinical evidence for life sciences companies. We offer comprehensive evidence-generation solutions that combine medical imaging, eCOA, precision motion, cardiac and respiratory endpoints.
For more than 50 years, Clario has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world. Our endpoint data solutions have been deployed over 30,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 70% of all FDA drug approvals since 2012.
For more information, go to Clario.com or follow us on LinkedIn.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account